Manufacturer
DUOPHARMA MANUFACTURING (BANGI) SDN BHD
Contents
Perindopril erbumine
Indication
Hypertension, Heart failure, Stable coronary artery disease.
Instruction
Should be taken on an empty stomach.
Drug interaction
Increased hypotensive effect with antihypertensive agents, diuretics, nitrates and baclofen. Increased risk of hyperkalaemia with K-sparing diuretics (e.g. spironolactone, eplerenone), K supplements, or other agents affecting serum K concentrations (e.g. trimethoprim, ciclosporin, heparin). May increase hypoglycaemic effect with insulin and oral hypoglycaemics agents. Increased risk of angioedema with mammalian target of rapamycin (mTOR) inhibitors (e.g. temsirolimus, sirolimus, everolimus), neutral endopeptidase (NEP) inhibitors (e.g. racecadotril), and dipeptidyl peptidase-IV (DPP-IV) inhibitors (e.g. sitagliptin, linagliptin). Concomitant use with NSAIDs including selective COX-2 inhibitors may result to renal function deterioration and reduced antihypertensive effect. May increase serum levels and toxicity of lithium. Coadministration with parenteral gold (e.g. Na aurothiomalate) may cause nitritoid reaction characterized by facial flushing, nausea, vomiting, and hypotension.Potentially Fatal: Increased risk of hypotension, hyperkalaemia, and changes in renal function with aliskiren. Increased risk of angioedema with sacubitril/valsartan. May cause anaphylactoid reactions with dextran sulfate in LDL apheresis.
Malaysia
